RIBOLIFE-B (06938) signs an exclusive global licensing agreement with Madrigal for a number of siRNA assets.

RIBOLIFE-B (06938) announced on February 11, 2026 (after trading hours) that the company and its subsidiary Ribocure Pharmaceuticals AB have entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ stock code: MDGL) regarding the development of six clinical pre-antisense small interfering RNA (siRNA) therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Under the agreement, the company has granted Madrigal exclusive global rights to utilize the company's RiboGalSTAR and siRNA chemical modification platform to develop, manufacture, and commercialize several clinical pre-single-target and dual-target siRNA assets. The group will receive an upfront payment of $60 million, and may receive up to $4.4 billion in milestone payments if certain development, regulatory, and commercial milestones are achieved, in addition to potential royalties on net sales. As of the date of this announcement, milestone payments under the agreement are subject to certain conditions to be met, therefore the final amount of milestone payments that the company may receive remains uncertain. This collaboration will utilize the company's validated liver-targeted RiboGalSTAR platform to develop a new therapy for MASH, marking a significant milestone on the company's path to becoming a leading innovative siRNA company globally. It will also accelerate the company's global development and commercialization strategy, introducing more targeted and effective therapies for unmet medical needs of MASH patients.